The Effects of Exenatide After Gastric Restriction

NCT00872378 · Unknown status

Last updated 2026-05-28

This clinical trial tested whether twice-daily exenatide, combined with lifestyle changes, helps reduce body weight in non-diabetic adults with severe obesity after weight-loss surgery.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 28 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2009-02 · est. completion 2010-12

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT00872378 ↗

Description as written by the study sponsor.

The purpose of this study is to describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide or placebo injections.

Treatments tested

Exenatide also known as BYETTA Drug

Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
Placebo Drug

Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).

Main thing measured	To describe change in body weight in non-diabetic morbidly obese patients after laparoscopic adjustable gastric banding (LAGB) with twice daily exenatide plus lifestyle modification plan or placebo plus lifestyle modification plan.
Sponsor	Advanced Specialty Care
Conditions studied	Morbid Obesity
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00872378 ↗